Kidney failure, in its most advanced form, is not simply a medical diagnosis. It is a life-altering event that confronts patients with a stark and often unfair choice: access expensive, lifelong treatment — or face a premature death. For millions of people around the world, particularly those living in low- and middle-income countries, that choice does not truly exist. The infrastructure is absent, the costs are prohibitive, and the political will to change this reality has historically fallen short.
End-stage renal disease (ESRD) — also referred to as kidney failure — represents the final, irreversible stage of chronic kidney disease (CKD), a condition in which the kidneys permanently lose their ability to filter waste products, regulate fluid balance, and maintain the body’s chemical equilibrium. Without renal replacement therapy (RRT) in the form of dialysis or kidney transplantation, ESRD is fatal. Understanding how this disease is distributed across the globe, why it disproportionately affects certain populations, and what the international kidney health community is doing to respond is not only a clinical priority — it is a matter of global health justice.
What Is End-Stage Renal Disease? A Brief Clinical Overview
Healthy kidneys perform a remarkable range of functions. They filter roughly 200 liters of blood per day, regulate blood pressure through hormonal signaling, manage electrolyte concentrations, stimulate red blood cell production, and activate vitamin D essential for bone health. When chronic kidney disease progresses — whether due to diabetes, high blood pressure, glomerulonephritis, or other causes — kidney function declines gradually over months or years, measured by the glomerular filtration rate (GFR).
ESRD is formally defined as a GFR below 15 milliliters per minute per 1.73 m² of body surface area, or the need to initiate renal replacement therapy regardless of GFR. At this stage, the kidneys can no longer sustain life without medical intervention. Symptoms at this point — fatigue, fluid retention, nausea, cognitive difficulty, and cardiovascular instability — are severe and rapidly worsening.
The three main forms of RRT are hemodialysis, peritoneal dialysis, and kidney transplantation. Hemodialysis, which involves filtering the blood through an external machine typically three times per week for three to four hours per session, is the most widely used modality globally. Peritoneal dialysis uses the lining of the abdominal cavity to filter waste and offers greater flexibility for home-based treatment. Kidney transplantation, when successful, provides the best long-term outcomes — but donor organ availability remains critically limited worldwide.
A Disease Without Borders: Global Incidence and Regional Disparities
The scale of the ESRD burden varies dramatically across world regions, and the data tell a sobering story. According to the United States Renal Data System (USRDS) Annual Data Report 2022, the United States recorded incident treated ESRD rates of approximately 380 per million population — among the highest in the world. By comparison, the ERA Registry (European Renal Association, Annual Report 2021) reported rates of 120 to 200 per million population across European countries, illustrating that even within high-income settings, significant variation exists in both disease frequency and treatment access.
These numbers reflect not only the true biological burden of disease but also the capacity of health systems to detect and treat it. In many low-income countries, ESRD prevalence is likely substantially underestimated because patients who cannot access treatment are simply not counted in registries — they die without a formal diagnosis.
The trajectory ahead is alarming. A systematic analysis published in The Lancet Diabetes & Endocrinology projected that global ESRD prevalence could reach 5.4 million by 2030 under a base-case scenario, driven primarily by the expanding burden of type 2 diabetes in Asia, Latin America, and sub-Saharan Africa — precisely the regions least equipped to respond.
Regional Snapshot: ESRD Rates Across World Regions
| Region | Approximate Incident ESRD Rate (per million population) | Primary Data Source | Access to RRT |
|---|---|---|---|
| United States | ~380 | USRDS Annual Report 2022 | Broadly available |
| Europe (range) | 120–200 | ERA Registry 2021 | Broadly available |
| High-income Asia (Japan, Taiwan) | 200–350 | National registry data | Broadly available |
| Latin America | 150–250 (estimated) | Regional registry data | Variable; urban-rural gaps |
| Sub-Saharan Africa | Largely unquantified | Limited registry infrastructure | Severely limited |
| South Asia | Variable; underreported | Emerging registry data | Limited, cost-dependent |
The Leading Causes of Kidney Failure: Diabetes and Hypertension
Two non-communicable diseases account for the majority of ESRD cases worldwide: diabetic nephropathy and hypertensive kidney disease. Together, they represent more than 60 percent of incident ESRD in high-income countries and a growing — though often underdocumented — proportion in lower-income settings.
Diabetic nephropathy develops in a subset of people living with both type 1 and type 2 diabetes. Chronically elevated blood glucose levels damage the small blood vessels within the kidney’s filtering units (glomeruli), initially causing increased protein leakage into the urine (proteinuria) and progressively impairing filtration function over years or decades. The explosive global rise of type 2 diabetes — now affecting over 500 million adults worldwide — has made diabetic nephropathy the single largest driver of ESRD growth in many regions.
Hypertensive kidney disease results from sustained high blood pressure that damages glomerular capillaries and the small arteries supplying kidney tissue, progressively scarring the organ. Given that hypertension affects more than one billion people globally and remains poorly controlled in many low-income settings, its contribution to the ESRD burden is substantial and growing.
Other significant causes include glomerulonephritis (immune-mediated inflammation of the kidney’s filtering units), polycystic kidney disease (a genetic disorder causing fluid-filled cysts to replace kidney tissue), and obstructive uropathy. In certain regions, environmental nephropathies such as aristolochic acid nephropathy or CKD of unknown etiology — observed in agricultural communities in Sri Lanka, Central America, and India — are emerging as important contributors.
Who Is Most at Risk? Racial, Ethnic, and Socioeconomic Disparities
Among the most troubling dimensions of the ESRD epidemic is its profound inequity. The disease does not fall evenly across populations — it clusters among those already burdened by poverty, limited healthcare access, and structural disadvantage.
In the United States, data from successive USRDS Annual Reports document that Black and Hispanic populations experience ESRD at two to four times the rates observed in non-Hispanic white populations. These disparities reflect a complex interplay of factors:
- Genetic risk: Variants in the APOL1 gene, present at higher frequency in individuals of West African ancestry, significantly increase the risk of non-diabetic kidney disease and rapid CKD progression. This genetic factor is an important — though not the sole — contributor to elevated ESRD rates in Black populations.
- Structural social determinants: Residential segregation, food insecurity, limited access to preventive care, and higher rates of uninsured status all contribute to delayed diagnosis and suboptimal management of CKD risk factors such as diabetes and hypertension.
- Differential access to nephrology care: Studies published in the Clinical Journal of the American Society of Nephrology and elsewhere have documented that Black and Hispanic patients are less likely to receive timely referral to nephrology specialists, less likely to be prepared for planned dialysis initiation, and less likely to be placed on kidney transplant waiting lists — a cascade of disparities that compounds biological risk with systemic barriers.
These patterns are not unique to the United States. Across the globe, marginalized and indigenous communities, rural populations, and those living in poverty face dramatically worse kidney health outcomes, reflecting both disease burden and healthcare system failures.
The Treatment Gap: When Life-Saving Therapy Is Out of Reach
Perhaps the starkest expression of global kidney health inequity is what might be called the treatment gap — the chasm between the number of people who develop ESRD and the number who actually receive renal replacement therapy.
The International Society of Nephrology has played a central role in documenting this crisis through the Global Kidney Health Atlas (GKHA). The 2019 GKHA report, published in Kidney International Supplements, documented that in more than 75 countries surveyed, the vast majority of patients reaching ESRD receive no renal replacement therapy at all, due to prohibitive costs and inadequate infrastructure. In low-income countries, the annual per-patient cost of hemodialysis frequently exceeds the national per capita income — making access structurally impossible for most individuals without government subsidy or external support.
The consequences of this treatment gap are devastating. When patients in low-income settings develop ESRD without access to dialysis or transplantation, the outcome is death — typically within weeks to months of kidney failure onset. This reality represents a profound global injustice that the nephrology community, led in part by ISN, is working to address.
Key Barriers to RRT Access in Low- and Middle-Income Countries
- High cost of dialysis consumables, equipment, and maintenance
- Shortage of trained nephrologists, dialysis nurses, and technicians
- Inadequate electricity, clean water, and physical infrastructure
- Absence of national kidney care plans or health financing schemes
- Limited availability of deceased and living donor transplant programs
- Lack of national CKD registries to quantify the burden and guide policy
The Role of ISN: Surveillance, Advocacy, and Global Action
The International Society of Nephrology has been at the forefront of global efforts to understand, document, and respond to the ESRD epidemic. Through its research, advocacy, and educational programs, ISN (International Society of Nephrology) works to improve kidney health outcomes across all income settings — with particular attention to the populations and countries left furthest behind.
The Global Kidney Health Atlas, developed by ISN in collaboration with national kidney societies and regional registries, represents one of the most comprehensive surveys of kidney care capacity and ESRD management ever undertaken. By mapping dialysis availability, transplantation capacity, workforce density, and health financing mechanisms across more than 125 countries, the GKHA provides the evidence base needed to advocate for change at national and international policy levels.
ISN has also advocated strongly for the integration of CKD prevention and early detection into broader non-communicable disease (NCD) programs. Chronic kidney disease shares major risk factors — particularly diabetes and hypertension — with cardiovascular disease and other NCDs. Integrating kidney health into existing NCD frameworks offers a cost-effective and scalable approach to reducing ESRD incidence before patients reach the point of needing dialysis.
A particularly visible expression of the International Society of Nephrology’s public engagement mission is World Kidney Day, co-sponsored with the International Federation of Kidney Foundations (IFKF). Held annually on the second Thursday of March, World Kidney Day uses scientifically developed themes and public education campaigns to raise awareness of CKD risk factors, promote early screening, and advocate for universal health coverage for kidney care. Each year’s theme addresses a specific dimension of the global kidney health challenge — from diabetes and hypertension management, to kidney health in women, to living well with kidney disease.
Prevention: The Most Powerful Tool in the Arsenal
Given the scale of the treatment gap and the economic impossibility of providing universal dialysis access in many low-income settings in the near term, prevention of CKD progression — and prevention of ESRD altogether — emerges as the most critical strategic priority.
The good news is that the majority of ESRD cases are, in principle, preventable or delayable through well-established interventions:
- Blood pressure control: Effective antihypertensive therapy, particularly with renin-angiotensin system (RAS) blockers such as ACE inhibitors or angiotensin receptor blockers (ARBs), substantially slows CKD progression in both diabetic and non-diabetic kidney disease.
- Glycemic management: Maintaining near-normal blood glucose levels in people with diabetes significantly reduces the risk of developing and progressing diabetic nephropathy. Newer drug classes, particularly SGLT2 inhibitors and GLP-1 receptor agonists, have demonstrated protective effects on kidney function that extend beyond glucose lowering alone.
- Proteinuria reduction: Proteinuria (protein in the urine) is both a marker of kidney damage and a driver of further injury. Reducing proteinuria through pharmacological and dietary interventions slows disease progression.
- Early CKD detection: Simple, inexpensive tests — a urine dipstick for proteinuria and a serum creatinine measurement to calculate estimated GFR — can identify CKD at an early stage when interventions are most effective. Expanding access to these tests through primary care and community health workers in low-resource settings is both feasible and impactful.
- Lifestyle modification: Smoking cessation, dietary sodium reduction, weight management, and regular physical activity all contribute to lower cardiovascular and kidney disease risk.
The Path Forward: National Kidney Care Plans and Universal Coverage
Effective responses to the global ESRD epidemic require more than clinical innovation — they require political commitment and health system transformation. The International Society of Nephrology has consistently advocated for the development of national kidney care plans in all countries, modeled on successful frameworks that integrate CKD screening, early management, and RRT access within broader health system strategies.
Key policy priorities identified by ISN and aligned organizations include:
- Universal health coverage provisions that explicitly include kidney care, including both CKD management and at least one modality of RRT
- Workforce development programs to train nephrologists, dialysis nurses, and allied health professionals in underserved regions
- National CKD registry development to quantify the burden, track trends, and evaluate interventions
- Research investment in locally appropriate, lower-cost dialysis technologies and expanded living
donor transplantation programs - Addressing social determinants of kidney health through intersectoral action on poverty, food security, and environmental exposures
Conclusion: A Call to Act on What We Already Know
The global epidemiology of end-stage renal disease is well documented. The causes are largely understood. The interventions that prevent disease progression are available, often at modest cost. And yet, millions of people around the world continue to develop ESRD and die without access to the treatment that could sustain their lives — not because medicine lacks answers, but because health systems and political systems have failed to deliver them equitably.
The data assembled by ISN (International Society of Nephrology), the USRDS, the ERA Registry, and national kidney societies paint a consistent picture: a disease burden concentrated in the most vulnerable populations, a treatment gap that follows the contours of global inequality, and an urgent need for coordinated action at clinical, policy, and public health levels.
The International Society of Nephrology remains committed to transforming this picture — through evidence generation, health system advocacy, capacity building, and the global mobilization of the nephrology community around a shared vision of kidney health for all. The path forward is demanding, but the scientific foundation is solid, and the moral imperative is clear. The challenge now is to act with the urgency the data demands.